Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$41.80 USD

41.80
478,250

+0.02 (0.05%)

Updated Jul 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and robust demand for its critical care products.

    Organigram (OGI) Catches Eye: Stock Jumps 11.7%

    by Zacks Equity Research

    Organigram (OGI) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

    Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem

    by Zacks Equity Research

    Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.

      Hologic's Second Molecular Test Gets EUA to Detect Coronavirus

      by Zacks Equity Research

      Hologic (HOLX) expects to boost testing capacity by combining its manufacturing ability for the latest EUA of test with its largest installed base of high-throughput molecular instruments.

        Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

        by Zacks Equity Research

        Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.

        SurModics (SRDX) Surpasses Q2 Earnings and Revenue Estimates

        by Zacks Equity Research

        SurModics (SRDX) delivered earnings and revenue surprises of 180.00% and 1.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

        Here's Why You Should Retain Inogen (INGN) Stock for Now

        by Zacks Equity Research

        Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects.

        AMN Healthcare Inks Deal to Address Healthcare System Needs

        by Zacks Equity Research

        This partnership is expected to boost AMN Healthcare's (AMN) Other Workforce Solutions segment.

        Earnings Preview: SurModics (SRDX) Q2 Earnings Expected to Decline

        by Zacks Equity Research

        SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

        Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec

        by Zacks Equity Research

        Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.

        Sriparna Ghosal headshot

        Here's Why You Should Retain Accuray in Your Portfolio

        by Sriparna Ghosal

        Investor confidence remains high in Accuray (ARAY) stock, thanks to solid prospects.

        Here's Why You Should Retain OPKO Health in Your Portfolio

        by Zacks Equity Research

        Investor confidence remains high in OPKO Health's (OPK) stock, thanks to solid prospects.

        Amedisys Gains on Expanding Hospice Arm, Favorable Demography

        by Zacks Equity Research

        Amedisys' (AMED) recent acquisitions in the Hospice arm aid the company's growth.

        Intersect Posts Preliminary Q1 Results, Withdraws '20 View

        by Zacks Equity Research

        Intersect (XENT) expects the impact of the coronavirus pandemic to substantially dampen revenues in the second quarter as well.

        Here's Why You Should Add ResMed (RMD) in Your Portfolio

        by Zacks Equity Research

        Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and combatting the coronavirus outbreak.

        Here's Why You Should Retain Allscripts in Your Portfolio Now

        by Zacks Equity Research

        Investor confidence remains high in Allscripts' (MDRX) stock, thanks to solid prospects.

          PRA Health Unit to Offer Free Access to Metys COVID-19 Module

          by Zacks Equity Research

          PRA Health's (PRAH) new module is likely to boost Data Solutions segment.

          Bio-Rad Rides on International Expansion Amid Cost Concerns

          by Zacks Equity Research

          Each of Bio-Rad's (BIO) key segments registers solid growth across three major geographies of America, Europe and Asia.

          Hologic (HOLX) Posts Q2 Preliminary Results, Withdraws View

          by Zacks Equity Research

          Investors remain optimistic with Hologic's (HOLX) balanced segmental preliminary revenue results for second-quarter fiscal 2020.

          Here's Why You Should Add Surmodics to Your Portfolio Now

          by Zacks Equity Research

          Investor confidence is high in Surmodics' (SRDX) stock,thanks to solid prospects.

          SurModics (SRDX) Down 22.1% Since Last Earnings Report: Can It Rebound?

          by Zacks Equity Research

          SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss

          by Zacks Equity Research

          Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

          SurModics (SRDX) Surpasses Q1 Earnings Estimates

          by Zacks Equity Research

          SurModics (SRDX) delivered earnings and revenue surprises of 266.67% and -0.89%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

          Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline

          by Zacks Equity Research

          SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

          Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline

          by Zacks Equity Research

          SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.